Search Within

Michael Morris

Formats
  1. Meeting Abstract (273)
  2. Journal Article (266)
  3. Review (19)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (580)
  2. Genitourinary Oncology Service (580)
  3. Solid Tumor Oncology Division (580)
  4. Radiology, Department of (163)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (140)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (21)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (238)
  2. Journal of Nuclear Medicine (43)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (248)
  2. American Association for Cancer Research (43)
  3. Society of Nuclear Medicine (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (39)
  6. Elsevier Inc. (27)

More Publishers

Results (580)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)
    Meeting Abstract

    Zhang, T.; Ballman, K. V.; Choudhury, A. D.; Chen, R. C.; Watt, C.; Wen, Y.; Shergill, A.; Zemla, T. J.; Emamekhoo, H.; Vaishampayan, U. N.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Ryan, C. J.; VanderWeele, D. J.; Heller, G.; Lewis, L. D.; Watt, C.; Chen, R. C.; Grubb, R.; Hahn, O. M.; Beltran, H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer
    Meeting Abstract

    Patel, V. G.; Zhong, X.; Shah, N. J.; Martina, L. P.; Hawley, J.; Lin, E.; Gartrell, B. A.; Febles, V. R. A.; Wise, D. R.; Qin, Q.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR) - A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth
    Meeting Abstract

    Pouliot, F.; Gorin, M. A.; Rowe, S. P.; Saperstein, L.; Josephson, D.; Carroll, P. R.; Wong, J. Y. C.; Pantel, A. R.; Cho, S. Y.; Gage, K. L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer
    Meeting Abstract

    Mitchell, A. P.; Mishra, A. A.; Bach, P. B.; Morris, M. J.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: A potential molecular vector for alpha-particle radioimmunotherapy
    Meeting Abstract

    Morris, M. J.; O' Donoghue, J. A.; Chetty, D.; Max, S.; Wanik, D.; Russell, M.; Nyima, T.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance)
    Meeting Abstract

    Halabi, S.; Yang, Q.; Starr, M. D.; Brady, J. C.; Armstrong, A. J.; George, D. J.; Kelly, W. K.; Beltran, H.; Morris, M. J.; Nixon, A. B.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging
    Meeting Abstract

    Durack, J. C.; Alva, A. S.; Preston, M. A.; Pouliot, F.; Saperstein, L.; Carroll, P. R.; Pienta, K. J.; Rowe, S. P.; Patnaik, A.; Probst, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer
    Meeting Abstract

    Chakraborty, G.; Hirani, R.; Nandakumar, S.; Kalidindi, T. M.; Fidele, D.; Rajanala, S. H.; Mazzu, Y. Z.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save